The global market for breast cancer imaging and biopsy technologies is expected to reach $5.8bn by 2022, a CAGR of 5.9%, driven by innovation technologies and machine-learning tools that serve as "second readers" to help radiologists triage images and find cancers. Many radiologists believe that mammography will remain the most widely used screening tool, but that digital breast tomosynthesis will ultimately become the gold standard. Here's a close look at the overall breast imaging and biopsy market, highlighting different modalities and key players, and offering the real-world use perspective from three radiologists at Kaiser Permanente, San Diego.
Breast cancer is the leading cancer in women globally and incidences continue to rise. To reverse this trend, several companies are focusing their efforts on developing imaging technologies that allow for earlier detection where treatment is more effective and less invasive.
While new developments in breast imaging and biopsy technologies have moved rapidly in recent years, concerns about the effectiveness of population-based screening programs remain. This, in turn, has led to...